Esperion Therapeutics (NASDAQ:ESPR) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Esperion Therapeutics (NASDAQ:ESPR) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04, Zacks reports.

Esperion Therapeutics Trading Down 7.1 %

Shares of ESPR stock opened at $1.58 on Tuesday. The company’s 50-day moving average price is $2.01 and its 200-day moving average price is $2.09. The stock has a market cap of $311.32 million, a price-to-earnings ratio of -2.47 and a beta of 1.01. Esperion Therapeutics has a twelve month low of $1.57 and a twelve month high of $3.94.

Analyst Upgrades and Downgrades

ESPR has been the subject of several recent analyst reports. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target for the company. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Tuesday, February 11th. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Finally, StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $6.75.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.